Tennessee Oncology Appoints Dr. Casey Chollet-Lipscomb as Chief Medical Officer

NASHVILLE, Tenn., March 10, 2025 /PRNewswire/ -- Tennessee Oncology, a nationally recognized independent oncology practice that treats nearly half of the cancer patients in the state across 36 clinics, is pleased to announce the appointment of Casey Chollet-Lipscomb, MD, as its new Chief Medical Officer.

Dr. Chollet-Lipscomb has been an integral part of Tennessee Oncology since joining the practice in 2014. She has served as Executive Vice President of Physician Services since last year, where she played a key role in advancing physician support, clinical quality, and health policy. Additionally, she has strengthened community partnerships and led significant initiatives across the practice. Dr. Chollet-Lipscomb has also served on Tennessee Oncology's Board of Directors since 2018 and previously led the Radiation Oncology Division as Managing Partner.

"I am thrilled to welcome Dr. Casey Chollet-Lipscomb as our new Chief Medical Officer," said Natalie Dickson, MD, Chief Executive Officer and President of Tennessee Oncology. "This appointment is a well-earned recognition of her exceptional leadership, unwavering dedication, and lasting impact on both our practice and the community we serve. I look forward to the continued success and innovation she will bring to Tennessee Oncology, and to the patients who will benefit from her leadership."

As Chief Medical Officer, Dr. Chollet-Lipscomb will continue to drive innovation and excellence in patient care while fostering new leadership opportunities within the practice. She will work to further advance Tennessee Oncology's mission of providing high-quality, compassionate cancer care.

Dr. Chollet-Lipscomb's leadership has been instrumental for Tennessee Oncology. In addition to her leadership roles at Tennessee Oncology, she is an active national advocate for oncology, serving on the Board of Directors for the American Society for Radiation Oncology (ASTRO) and working to influence cancer care policy at both the federal and state levels.

Johnetta Blakely, MD will continue her role as Executive Vice President of Quality and Clinic Operations, and Ted Arrowsmith, MD will remain in his position as Executive Vice President of Therapeutics. Both are highly valued members of the leadership team, and they, along with Dr. Chollet-Lipscomb, serve on Tennessee Oncology's Board of Directors. All three are practicing physicians—Dr. Blakely in Cookeville, Dr. Chollet-Lipscomb in Nashville, and Dr. Arrowsmith in Chattanooga.

Dr. Chollet-Lipscomb earned her medical degree from the University of Tennessee, completed her residency at Loyola University Medical Center in Chicago, and served as an attending physician at Duke University prior to joining Tennessee Oncology.

About Tennessee Oncology:
Tennessee Oncology, one of the nation's largest community-based cancer care practices, is home to one of the leading clinical trial networks in the country. Established 1976 in Nashville, Tennessee Oncology's mission remains unchanged: To provide access to high-quality cancer care and the expertise of clinical research for all patients, at convenient locations within their community and close to their home. Our growing network of physicians and locations is based on this mission. For more information, visit www.tnoncology.com.

SOURCE Tennessee Oncology